- Johnson Controls International PLC (NYSE:JCI) has signed a joint development agreement with Phylagen, a biotechnology company in microbiome optimization of indoor environments.
- The agreement includes a strategic investment in Phylagen. The financial terms of the deal were not disclosed.
- Through this agreement, the companies develop cutting-edge technology that leverages the science of building microbiomes to improve the future of healthy buildings.
- Price Action: JCI shares traded higher by 1.87% at $74.18 on the last check Thursday.
Bernstein Initiates Coverage On BeiGene with Outperform Rating, Announces Price Target of $431
Bernstein initiates coverage on BeiGene (NASDAQ:BGNE) with a Outperform rating and announces Price Target of $431.
